RARE - Ultragenyx Corp Market Cap to Revenue Ratio

Symbol and logo of brand Ultragenyx Pharmaceutical Inc. (RARE)

The non-cyclical demand for genetic therapies makes the Ultragenyx Pharmaceutical (RARE) business resilient to crises, as confirmed by the current P/S level on the GURU.Markets service base chart, where the parameter mark equals 2.20. Its status as an exclusive provider of life-saving treatments guarantees high margins. Meanwhile, price stability is supported by the successful launch of new drugs and sufficient capital for clinical trials.

RARE: Ultragenyx Corp Price-to-Revenue Ratio 07/04/2022 - 11/17/2026

Analytical breakdowns for Ultragenyx Corp (RARE)

- current quotes and average value forecast:
Fundamental company analysis:Ultragenyx Pharmaceutical Inc., RARE
Finished products of Ultragenyx Pharma

The P/S ratio reflects the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of sales. By analyzing the price/sales ratio trend, an investor can identify an overvaluation of Ultragenyx Pharmaceutical (RARE), which is critical given the current liquidity shortage and the company's high dependence on external financing due to costly R&D.

Competitors of Ultragenyx Pharmaceutical

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|Market Cap to Revenue BEAM|P/S Multiple Sarepta Corp|Price-to-Revenue Ratio Twist Bioscience, Inc. (TWST)|Market Cap to Revenue 10x Genomics TXG|Price-to-Revenue Ratio Intellia Therapeutics NTLA|Market Cap to Sales Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Price-to-Revenue Ratio|Price to Sales Wave Pharma|mazetx.com (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio